Drug Trial Radar · NCT06731101
Stellate Ganglion Block Versus Oral Medication in Treatment of Palmar Hyperhidrosis
Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Jan 15, 2025
Primary completion
Dec 10, 2025
Study completion Jan 1, 2026
Sponsor
- Lead sponsor
- Fayoum UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 12, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of the study is to compare between ganglion block versus combined oral anticholinergic and antidepressant drugs on treatment of palmar hyperhidrosis
Conditions
- Palmar Hyperhidrosis
Interventions
Bupivacaine + Lidocaine +dexamethasoneDrug
Sonar guided block of Stellate Ganglion By Bupivacaine + Lidocaine
Tryptizole + LibraxDrug
Tryptizole + Librax
Primary outcomes
What the sponsor says the trial is designed to measure.
- SecretionsTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taha mohamed agmy
Al Fayyum, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.